<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385667</url>
  </required_header>
  <id_info>
    <org_study_id>LVN-IUS vs Megace for AEH</org_study_id>
    <nct_id>NCT04385667</nct_id>
  </id_info>
  <brief_title>LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia</brief_title>
  <official_title>The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial is aimed to compare the efficacy between Megestrol acetate
      (MA) and the levonorgestrel intrauterine system (LNG-IUD) regarding the ability and duration
      to produce complete regression for cases with atypical endometrial hyperplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 25% of cases with endometrial cancer and atypical hyperplasia occur in premenopausal
      women. The progressively increasing trend of delay in first conception increases such
      patients who wish to have children.3 The recommended treatment for EH without atypia is
      primarily hormonal, whereas the preferred treatment for EH with atypia is hysterectomy given
      the significant risk for both concurrent and subsequent development of endometrial carcinoma.
      A dilemma results when EH with atypia is diagnosed in women who wish to retain fertility or
      declining doing hysterectomy due to concomitant medical morbidities. In these women, a trial
      of hormone therapy can be considered.4,5 In recent years, progestin therapy has been
      successfully used to treat selected women with endometrial cancer and atypical hyperplasia
      who desire to preserve fertility or having severe medical co-morbidities precluding
      (immediate) surgery. The most common progestin regimens include Megestrol acetate (MA) and
      the levonorgestrel intrauterine system (LNG-IUD).5-7
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate to accomplish complete regression of atypical endometrial hyperplasia</measure>
    <time_frame>15 month</time_frame>
    <description>The success rate to accomplish complete regression of atypical endometrial hyperplasia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>a- Duration needed to accomplish the complete recovery</measure>
    <time_frame>15 months</time_frame>
    <description>time till regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>b- The partial regression and failure rates.</measure>
    <time_frame>8 months</time_frame>
    <description>incidence of partial regression and therapy failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c- Differential response rates between premenopausal and postmenopausal cases.</measure>
    <time_frame>15 months</time_frame>
    <description>response rate in both premenopause and postmenopause women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>d- The risk of thromboembolic complications</measure>
    <time_frame>15 months</time_frame>
    <description>incidence of thromboembolism with therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>f- Metabolic complications rates</measure>
    <time_frame>15 months</time_frame>
    <description>occurence of diabetes or hypertension ...ets</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atypical Endometrial Hyperplasia</condition>
  <arm_group>
    <arm_group_label>levonorgestrel intrauterine system (LNG-IUD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levonorgestrel intrauterine system (LNG-IUD) applied.
Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.
Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.
Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Megestrol acetate (MA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Megesterol arm will receive 160 mg daily
Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.
Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.
Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>levonorgestrel intrauterine system (LNG-IUD)</intervention_name>
    <description>progestin delivery for regression of atypical endometrial hyperplasia</description>
    <arm_group_label>levonorgestrel intrauterine system (LNG-IUD)</arm_group_label>
    <other_name>• Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Megesterol 160 mg daily</intervention_name>
    <description>progestin delivery for regression of atypical endometrial hyperplasia</description>
    <arm_group_label>Megestrol acetate (MA)</arm_group_label>
    <other_name>• Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All cases with evidence of atypical endometrial hyperplasia declining doing hysterectomy

        Exclusion Criteria:

          -  Cases with evidence of associated endometrial cancer.

          -  Cases with simple hyperplasia without atypia.

          -  Patients failed to collect at least 2 endometrial samples during treatment course.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr Alnemr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine- Zagazig university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hytham Atia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine- Zagazig university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hytham Atia, M.D.</last_name>
    <phone>+966538308500</phone>
    <email>hythamatia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amr Alnemr, M.D.</last_name>
    <phone>+201224581528</phone>
    <email>amrabmohsen@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <state>Sharkia</state>
        <zip>44511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AMR ELNEMR, MD</last_name>
      <phone>+201224581528</phone>
      <email>IRB_123@med.zu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012 Sep-Oct;19(5):562-71. doi: 10.1016/j.jmig.2012.05.009. Epub 2012 Aug 3. Review.</citation>
    <PMID>22863972</PMID>
  </reference>
  <reference>
    <citation>Salman MC, Usubutun A, Boynukalin K, Yuce K. Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. J Gynecol Oncol. 2010 Jun;21(2):97-101. doi: 10.3802/jgo.2010.21.2.97. Epub 2010 Jun 30.</citation>
    <PMID>20613899</PMID>
  </reference>
  <reference>
    <citation>Zhou R, Yang Y, Lu Q, Wang J, Miao Y, Wang S, Wang Z, Zhao C, Wei L. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol Oncol. 2015 Dec;139(3):424-8. doi: 10.1016/j.ygyno.2015.09.078. Epub 2015 Sep 30.</citation>
    <PMID>26428941</PMID>
  </reference>
  <reference>
    <citation>Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Dec;203(6):547.e1-10. doi: 10.1016/j.ajog.2010.07.037. Review.</citation>
    <PMID>20934679</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 9, 2020</study_first_submitted>
  <study_first_submitted_qc>May 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Hytham Atia</investigator_full_name>
    <investigator_title>Associate Professor Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>atypical endometrial hyperplasia</keyword>
  <keyword>levonorgestrel intrauterine system</keyword>
  <keyword>Megestrol acetate</keyword>
  <keyword>partial regression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

